STOCK TITAN

PureTech Health Plc - PRTC STOCK NEWS

Welcome to our dedicated news page for PureTech Health Plc (Ticker: PRTC), a resource for investors and traders seeking the latest updates and insights on PureTech Health Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PureTech Health Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PureTech Health Plc's position in the market.

Rhea-AI Summary
PureTech Health plc (PRTC) announces participation in upcoming investor conferences, showcasing key management team members and presenting webcasts for investor access.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
PureTech Health's Japanese partner, Shionogi & Co. Ltd, submits Akili's digital therapeutic SDT-001 for marketing approval in Japan, a localized version of AKL-T01. The Phase 3 clinical trial results show significant improvements in pediatric ADHD patients. Positive outcomes pave the way for potential nationwide marketing approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
Rhea-AI Summary
PureTech Health plc (PRTC) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) announced that its Founded Entity, Karuna Therapeutics, Inc., and Bristol Myers Squibb (NYSE: BMY) have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
acquisition
-
Rhea-AI Summary
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) announced that its Founded Entity, Karuna Therapeutics, Inc., and Bristol Myers Squibb (NYSE: BMY) have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
47.71%
Tags
acquisition
-
Rhea-AI Summary
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) announced that its Founded Entity, Karuna Therapeutics, Inc., and Bristol Myers Squibb (NYSE: BMY) have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.93%
Tags
acquisition
Rhea-AI Summary
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) announced favorable safety profile and anti-tumor activity of LYT-200 in combination with tislelizumab. Initial results show promise for patients with head and neck cancers, where historical outcomes are poor with response rates of less than 20 percent on standard-of-care treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.68%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
none
Rhea-AI Summary
Karuna Therapeutics (KRTX) announced positive results from its Phase 1b open-label, eight-week inpatient trial evaluating the effect of KarXT on 24-hour ambulatory blood pressure in adults with schizophrenia. KarXT demonstrated a mean change from baseline to week 8 in 24-hour ambulatory systolic blood pressure of -0.59 mmHg, ruling out a clinically meaningful increase in blood pressure. The trial showed that KarXT was generally well tolerated, with a side effect profile consistent with prior trials in the EMERGENT program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.77%
Tags
clinical trial
PureTech Health Plc

Nasdaq:PRTC

PRTC Rankings

PRTC Stock Data

709.97M
154.61M
0.04%
Investment Advice
Finance and Insurance
Link
US
Boston

About PRTC

PureTech Health is a biotechnology company which develops medicines to combat serious diseases.